Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2025)

Mimedx's Asset Writedowns and Impairment history spans 9 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 641.41% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $6.5 million, up 455.41%, while the annual FY2025 figure was $6.5 million, 994.96% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $3.4 million at Mimedx, up from $2.1 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.4 million in Q4 2025 and bottomed at -$60000.0 in Q1 2023.
  • The 5-year median for Asset Writedowns and Impairment is $388500.0 (2022), against an average of $800625.0.
  • The largest YoY upside for Asset Writedowns and Impairment was 7145.0% in 2023 against a maximum downside of 85.4% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $100000.0 in 2021, then crashed by 80.0% to $20000.0 in 2022, then skyrocketed by 7145.0% to $1.4 million in 2023, then tumbled by 68.67% to $454000.0 in 2024, then surged by 641.41% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Asset Writedowns and Impairment are $3.4 million (Q4 2025), $2.1 million (Q3 2025), and $351000.0 (Q2 2025).